School of Life & Health Sciences Aston University Aston TriangleBirmingham B4 7ETUK
email: M.J.Tisdale@aston.ac.uk telephone: +44 (0) 121 204 4021 fax: +44 (0) 121 204 3743
Chronic and Communicable Conditions
Aston Research Centre for Healthy Ageing (ARCHA)
I joined the Cancer Research Campaign Experimental Chemotherapy Group in the Department of Pharmacy at Aston University as Senior Research Fellow in October 1980. Prior to that I spent 8 years as Lecturer in the Department of Biochemistry at St Thomas’s Hospital Medical School, University of London, one year as Scientific Officer at Rothamstead Experimental Station, Harpenden and one year as MRC Fellow at the Institute of Cancer Research.
• 1989–date: Professor of Cancer Biochemistry, Aston University• 1992-95: Head of Department, Pharmaceutical and Biological Sciences, Aston University• 1984-89: Reader, Department of Pharmaceutical Sciences, Aston University • 1981-84: Senior Research Fellow, CRC Experimental Chemotherapy Group, Aston University • 1972-81: Lecturer Department of Biochemistry, St Thomas’s Medical School• 1971-72: Scientific Officer, Rothamstead Experimental Station• 1970-71: MRC Fellow, Institute of Cancer Research
Mainly related to cancer causation, biology treatment and associated conditions e.g. cachexia.
Modules: PH3 CM1, PH1 CM1, BY3 CM1, BY1 CM1, BY2 BD1, PH3 MC1
Cancer cachexia, mechanism and treatment. Treatment of obesity and type 2 diabetes.
• Signal transduction pathways involved in muscle catabolism by proteolysis-inducing factor (PIF)• Cloning and sequencing of cellular receptor for PIF• Cloning and expression of PIF• Investigation of antibodies to the PIF receptor as anticachectic agents• Action of eicosapentaenoic acid (EPA) in preventing muscle catabolism by PIF• Role of EPA in attenuating muscle catabolism in catabolic states other than cancer cachexia• Clinical evaluation of EPA in the treatment of cancer cachexia
Title of Project
Evaluation of zinc-alpha 2-glycoprotein for the treatment of obesity
Anticachectic activity of a novel agent
Ross Products Division
Effect of ingredients in an animal model of cachexia
British Technology Group
Studies on the PIF receptor
Novartis Medical Nutrition
Investigation into the mechanism for depression of protein synthesis in cancer
To determine whether angiotensin II has a direct effect on muscle protein degradation
The potential therapeutic use of zinc-alpha2-glcyoprotein for obesity and type II diabetes
Cloning and expression of a muscle receptor for a cancer-cachectic factor
Novartis Consumer Health
Studies on cancer cachexia